NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Cantabil FY26 PAT Jumps 28% to ₹95.8 Cr; Total Store Count Reaches 652
Cantabil Retail India Limited delivered robust financial results for FY26, with annual revenue growing 18% to ₹852.6 crore and Profit After Tax (PAT) increasing by 28% to ₹95.8 crore. The company expanded its retail footprint significantly, adding 53 new stores during the year to reach a total of 652 stores across 308 cities. Operational metrics remained healthy, with Same Store Growth (SSG) at 5.24% and a 13.33% increase in annual volume. The company also maintained industry-leading return ratios, reporting an ROCE of 40.2% and ROE of 22.0% for the fiscal year.
முக்கிய அம்சங்கள்
Annual Revenue from Operations grew by 18% YoY to ₹852.6 crore in FY26Full-year PAT increased by 28% to ₹95.8 crore, with EBITDA margins improving to 31.0%The company added 53 new stores in FY26, bringing the total retail area to 9.15 lakh sq. ft.Volume growth for the year stood at 13.33% YoY, supported by a 5.24% SSGStrong profitability metrics with ROCE at 40.2% and ROE at 22.0% for FY26
👀 கவனிக்க வேண்டியவை
Investors should view the consistent double-digit growth in revenue and profitability, coupled with aggressive store expansion and high return ratios, as a sign of strong execution. Monitor the sustainability of SSG and margins as the company continues its expansion into new cities.
Cantabil Reports Record FY26 Profit of ₹95.8 Cr, Up 28% YoY; EBITDA Margins Hit 31%
Cantabil Retail India Limited delivered a strong performance for FY26, with annual revenue growing 18% to ₹852.6 crores and PAT rising 28% to ₹95.8 crores. The company achieved an industry-leading EBITDA margin of 31.0%, up from 28.4% in the previous year, driven by operational efficiencies and scale. Q4 FY26 also showed robust growth, with a 30% increase in PAT to ₹29.2 crores. With a network of 652 stores and a healthy Same Store Sales Growth (SSSG) of 5.24%, the company continues to expand its footprint in the value fashion segment.
முக்கிய அம்சங்கள்
Annual Revenue from Operations increased by 18% YoY to ₹852.6 crores in FY26.EBITDA margins expanded significantly to 31.0% in FY26 compared to 28.4% in FY25.Net Profit (PAT) for the full year reached a record ₹95.8 crores, a 28% growth over FY25.Reported a healthy Same Store Sales Growth (SSSG) of 5.24% for the fiscal year.Retail footprint expanded to 652 stores across India, covering 9.15 lakh sq. ft.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and consistent 26% PAT CAGR over five years as indicators of high operational efficiency. The stock remains a strong contender in the retail apparel space due to its robust store network and healthy SSSG.
Hester Biosciences Q4 FY26 PAT Surges 174% Driven by Poultry Segment and Exceptional Gains
Hester Biosciences reported a strong performance for Q4 FY26, with standalone revenue growing 22% and PAT jumping 174% YoY. The Poultry Healthcare division was the primary growth engine, recording 41% growth in Q4, while the consolidated annual PAT doubled, partly aided by exceptional income from a stake sale in Texas Lifesciences. The company has successfully capitalized its new Fill-Finish and BSL-3 facilities and received licenses for the H9N2 Avian Influenza vaccine. Despite earlier delays in government tenders, the company executed the supply of 6.3 crore PPR vaccine doses in the final quarter.
முக்கிய அம்சங்கள்
Standalone Q4 PAT increased by 174% YoY, while consolidated FY26 PAT grew by 100% to reach record levels.Poultry Healthcare division revenue grew 41% in Q4 and 21% for the full financial year FY26.Supplied 6.3 crore doses of PPR vaccine in Q4 FY26, signaling a recovery in the Animal Healthcare tender business.Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, targeting the private commercial market.Capitalized new Fill-Finish and BSL-3 facilities to enhance drug product capacity and operational efficiency.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition toward higher-margin biologicals and the scaling of the H9N2 vaccine. The successful capacity expansion and recovery in tender execution provide a positive outlook for FY27.
IDBI Bank Board Approves Raising Up to ₹10,000 Crore via Infrastructure Bonds
IDBI Bank's Board of Directors has approved a proposal to raise up to ₹10,000 crore through the issuance of long-term rupee-denominated bonds. These funds are specifically designated for financing infrastructure projects and affordable housing. The capital will be raised in one or more tranches via private placement in the domestic market through March 31, 2027. This strategic move aims to strengthen the bank's long-term resource base and support credit growth in high-priority sectors.
முக்கிய அம்சங்கள்
Approved issuance of Long Term Rupee denominated Bonds up to ₹10,000 croreFunds earmarked for Infrastructure and Affordable Housing financingIssuance to be conducted via private placement in the domestic marketFundraising window extends until March 31, 2027The move follows the Board Meeting held on May 16, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the bank's ability to deploy this capital into high-yield infrastructure projects, which could improve long-term margins. The fundraise is a positive indicator of the bank's growth intentions in the housing and infra segments.
MobiKwik Turns Profitable in Q4 FY26 with ₹4.4 Cr PAT; Payments GMV Hits Record ₹52,400 Cr
One MobiKwik Systems achieved a significant financial turnaround in FY26, reporting back-to-back profitable quarters in the second half of the year. Q4 FY26 saw a PAT of ₹4.4 crore and an EBITDA of ₹17.4 crore, a massive swing from the previous year's losses. The company's payments GMV reached an all-time high of ₹52,400 crore in Q4, driven by UPI growth that outpaced the industry by 6.5x. Management is now pivoting towards four growth engines, including merchant payments and an NBFC license, aiming for a 10x scale-up in merchant revenue by FY28.
முக்கிய அம்சங்கள்
Achieved Q4 FY26 PAT of ₹4.4 crore (₹8.1 crore excluding one-time wage code charges) and EBITDA of ₹17.4 crore.Full-year FY26 EBITDA improved by ₹74.2 crore to reach near break-even at -₹5.2 crore.Payments GMV grew 58% YoY to ₹52,400 crore, with customer-initiated UPI transactions growing 170% YoY.Financial services gross margin reached a record 59% in Q4, with super-prime customer mix rising to 32%.Targeting 10x revenue growth in offline merchant payments and 10x GMV for Zaakpay by FY28.
👀 கவனிக்க வேண்டியவை
Investors should view the shift to profitability and the focus on super-prime lending as a positive sign of sustainable growth. Monitor the progress of the NBFC license application and the execution of the 10x merchant payment scale-up targets.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SBI Reports Record FY26 Net Profit of 80,032 Crores with Strong Asset Quality
State Bank of India (SBI) delivered a robust performance for FY26, reporting a record net profit of 80,032 crores, up 12.88% YoY. The bank maintained a healthy domestic Net Interest Margin (NIM) of 3.03% and achieved a credit growth of 16.87%, significantly outpacing deposit growth of 11.03%. Asset quality remains at a multi-decade high with Gross NPA at 1.49% and Net NPA at 0.39%. Management has guided for 13-14% credit growth in FY27 while maintaining an ROA of over 1%.
முக்கிய அம்சங்கள்
Record annual net profit of 80,032 crores with a Return on Equity (ROE) of 18.5% in Q4FY26.Asset quality improved with Gross NPA at 1.49% and Net NPA at 0.39%, the lowest in two decades.Credit growth was robust at 16.87% YoY, while the domestic Credit-Deposit (CD) ratio improved to 73.08%.Capital Adequacy Ratio (CAR) strengthened to 15.4%, providing a 115 bps YoY improvement for future growth.Digital transformation continues with YONO crossing 10 crore users and 66% of new savings accounts being opened digitally.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in SBI's ability to maintain high asset quality and a Return on Assets (ROA) above 1% at such a large scale. The bank remains a preferred play in the Indian banking sector due to its strengthening liability franchise and digital leadership.
Hester Biosciences FY26 Consolidated Revenue Hits ₹332.6 Cr; PAT Surges to ₹57.5 Cr
Hester Biosciences reported a strong financial performance for FY 2025-26, with consolidated revenue reaching ₹332.60 crore. The company witnessed a significant recovery in profitability, with consolidated Profit After Tax (PAT) jumping to ₹57.48 crore from ₹21.17 crore in the previous fiscal year. Hester maintains a dominant 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine. The company is strategically diversifying, with the Animal Healthcare division now contributing 38% to consolidated revenue.
முக்கிய அம்சங்கள்
Consolidated revenue grew to ₹332.60 crore in FY26 compared to ₹311.10 crore in FY25.Consolidated PAT surged to ₹57.48 crore, a substantial increase from ₹21.17 crore in the prior year.Maintains a 35% market share in the Indian poultry vaccine segment as the second-largest manufacturer.Annual manufacturing capacity stands at 8.6 billion doses in India, 1.24 billion in Nepal, and 1.5 billion in Africa.Animal Healthcare division's revenue contribution rose to 38% on a consolidated basis, up from 29% on a standalone basis.
👀 கவனிக்க வேண்டியவை
Investors should view the sharp turnaround in profitability and margin expansion as a positive sign of operational efficiency. The company's leading position in global vaccine banks and expansion into the Petcare segment provide long-term growth visibility.
Hester Biosciences: Promoters Ravin and Bela Gandhi Seek Reclassification of 9.45% Stake to Public
Hester Biosciences has received formal requests from two members of its promoter group, Mr. Ravin Gandhi and Ms. Bela Gandhi, to be reclassified as public shareholders. Mr. Ravin Gandhi holds a 4.74% stake (403,320 shares) and recently resigned from the Board, while Ms. Bela Gandhi holds a 4.71% stake (400,635 shares). Together, they represent 9.45% of the company's voting rights and have declared they no longer exercise management control or hold special rights. The company is now initiating the necessary regulatory steps under SEBI guidelines to process these requests.
முக்கிய அம்சங்கள்
Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake) have applied for reclassification from 'Promoter' to 'Public' category.The combined shareholding involved in the reclassification request totals 803,955 equity shares or 9.45% of the company.Mr. Ravin Gandhi resigned from the Board of Directors effective May 12, 2026, to facilitate this transition.Ms. Bela Gandhi confirmed she has had no involvement in company management for the last 12 years.The reclassification is subject to approval from the company's shareholders and the stock exchanges under SEBI Regulation 31A.
👀 கவனிக்க வேண்டியவை
Investors should view this as a standard regulatory restructuring of shareholding; however, monitor if this leads to any future secondary market sales by these individuals once they are classified as public. The move does not impact the company's day-to-day operations or business fundamentals.
Hester Biosciences Q4 PAT Surges 174% to INR 26.38 Cr; Declares INR 11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to INR 93.71 crore. Net profit for the quarter saw a significant jump of 174% YoY to INR 26.38 crore, bolstered by an exceptional gain of INR 6.99 crore from a subsidiary sale. The Board has recommended a healthy dividend of INR 11 per share (110% of face value). The Poultry Healthcare segment continues to be the primary growth engine, while the company also confirmed the re-appointment of Ms. Priya Gandhi as Executive Director.
முக்கிய அம்சங்கள்
Standalone Q4 FY26 PAT rose to INR 263.84 million from INR 96.35 million in the previous year's quarter.Full-year FY26 PAT increased by 63.6% to INR 521.00 million compared to INR 318.42 million in FY25.Recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.Poultry Healthcare segment revenue grew 41% YoY in Q4 to INR 650.72 million.Recorded an exceptional gain of INR 69.96 million in Q4 FY26 from the sale of investment in a subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin improvement and the strong recovery in the poultry segment. The healthy dividend payout and profit growth make this a positive update for long-term shareholders.
Hester Biosciences Recommends ₹11 Dividend; FY26 PAT Surges 64% to ₹521 Million
Hester Biosciences has recommended a final dividend of ₹11 per share for FY26, representing a 110% payout on face value. The company reported a strong financial performance with annual standalone Profit After Tax (PAT) rising 64% to ₹521 million, driven by significant growth in the Poultry Healthcare segment. Quarterly performance was particularly robust, with Q4 PAT jumping to ₹263.84 million from ₹96.35 million in the previous year. Additionally, the board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a three-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹11 per equity share (110%) for the financial year 2025-26.Standalone annual Profit After Tax (PAT) increased by 63.6% YoY to ₹521 million.Q4 FY26 Revenue from operations grew 22% YoY to ₹937.13 million compared to ₹766.72 million.Poultry Healthcare segment revenue grew to ₹2,061.31 million in FY26 from ₹1,665.83 million in FY25.Earnings Per Share (EPS) improved significantly to ₹61.24 for FY26 compared to ₹37.43 in FY25.
👀 கவனிக்க வேண்டியவை
Investors should consider the strong bottom-line growth and healthy dividend payout as a sign of improved operational efficiency. The significant jump in Q4 margins and Poultry segment growth makes this a positive development for long-term holders.
Biocon reported a resilient Q4 FY26 with adjusted operating revenue growth of 10% YoY, driven by a 12% rise in the Biosimilars segment. The company successfully completed the integration of its biosimilars and generics businesses within 100 days, achieving a group EBITDA of INR 1,073 crores at a 23% margin. Key product milestones include the US launch of denosumab biosimilars and FDA approval for liraglutide. Management highlighted that the heavy investment phase is now complete, shifting focus toward deleveraging and improving return on capital employed (ROCE).
முக்கிய அம்சங்கள்
Biosimilars revenue grew 12% YoY to INR 2,756 crores with a robust EBITDA margin of 26%.Generics revenue, excluding one-time lenalidomide gains, grew 13% YoY to INR 847 crores.Full-year FY26 adjusted EBITDA increased 25% YoY with a 200 bps margin expansion to 22%.Successfully launched denosumab biosimilars (Bosaya and Aukelso) in the US market post-quarter.Net profit before exceptional items for the full year FY26 stood at INR 436 crores.
👀 கவனிக்க வேண்டியவை
Investors should focus on the scale-up of high-value launches like liraglutide and denosumab in H2 FY27, which are expected to drive further margin expansion. The completion of the integration phase and ongoing deleveraging reduce structural risks, making it a watch for long-term value creation.
Birla Corp Q4 FY26: EBITDA Hits INR 1,000/ton; Blended Cement Share Rises to 88%
Birla Corporation reported a strong Q4 FY26 with EBITDA reaching approximately INR 1,000 per ton, driven by a strategic shift toward blended cement (88% share) and premium brands. The company achieved its highest-ever annual volume with a 4% growth, while reducing lead distances to 337 km. Management is targeting a capacity of 27.5 million tons by FY29 through the Maihar Line-II expansion. Operational efficiency is expected to improve further as the Bikram coal block reaches full capacity, offering significant fuel cost savings.
முக்கிய அம்சங்கள்
Q4 EBITDA reached approximately INR 1,000 per ton, while full-year EBITDA stood at ~INR 800 per ton.Blended cement share improved significantly from 82% to 88% year-on-year, enhancing margins.Lead distance reduced from 360 km to 337 km, improving logistical efficiency and reducing costs.Capacity expansion plan to reach 27.5 MTPA by FY29 with a total capex of INR 4,000-4,500 crores.Bikram coal block production to provide cost arbitrage with landed cost of INR 1.0-1.05 vs domestic coal at INR 1.45.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful premiumization strategy and the upcoming cost benefits from the Bikram coal block. The stock remains a solid mid-cap cement play with a clear path to 27.5 MTPA capacity by FY29.
Ambika Cotton Mills Board Meeting on May 26 for FY26 Results and Final Dividend
Ambika Cotton Mills Limited has scheduled a board meeting on May 26, 2026, to approve the audited financial results for the fiscal year ending March 31, 2026. The board will also consider the declaration of a final dividend for the financial year 2025-26. This meeting is a key event for shareholders to evaluate the company's annual profitability and cash distribution plans. The notification was filed with BSE and NSE on May 14, 2026, in compliance with SEBI regulations.
முக்கிய அம்சங்கள்
Board meeting scheduled for May 26, 2026, to approve FY26 audited results.Consideration of a final dividend for the financial year 2025-26.The meeting will review performance for the full year ended March 31, 2026.Compliance notice issued under Regulation 29 of SEBI (LODR) Regulations.
👀 கவனிக்க வேண்டியவை
Investors should track the May 26 outcome to assess the dividend yield and the company's operational performance for the full year.
NBIFIN Recommends 15% Dividend and Reports FY26 Net Profit Growth to ₹16.70 Crore
N. B. I. Industrial Finance Company has reported a strong financial performance for the fiscal year ended March 31, 2026, with net profit before tax rising to ₹16.70 crore from ₹10.86 crore in the previous year. The Board has recommended a dividend of ₹0.75 per share (15% on face value of ₹5), which is subject to approval at the upcoming AGM on August 21, 2026. The company's investment portfolio, a major component of its balance sheet, grew significantly to ₹3,512.18 crore from ₹2,722.92 crore year-on-year. Total assets expanded by approximately 29%, reflecting robust growth in the company's financial base.
முக்கிய அம்சங்கள்
Recommended a dividend of 15% amounting to ₹0.75 per equity share of ₹5 face value for FY 2025-26.Net profit before tax increased by 53.8% YoY to ₹1,669.61 lakhs compared to ₹1,085.61 lakhs in FY25.Total investments rose to ₹3,51,218.49 lakhs from ₹2,72,291.63 lakhs in the previous fiscal year.Annual General Meeting (AGM) to be held on August 21, 2026, to finalize the dividend and financial results.Statutory auditors issued an unmodified opinion, confirming the reliability of the reported financial data.
👀 கவனிக்க வேண்டியவை
Investors should consider the 53% growth in pre-tax profit and the consistent dividend payout as positive indicators of financial health. The significant expansion in the investment book warrants a closer look at the underlying asset quality and market exposure.
BirlaNu Limited, formerly known as HIL Limited, has released its Q4 and FY26 investor presentation, highlighting a major rebranding and a strategic vision to achieve $1 billion in revenue. The company operates 33 manufacturing facilities globally and has a massive distribution network of over 30,000 retail points. Key product capacities include 1.1 million MT in Roofs and over 100k MTPA in Pipes and Fittings. The presentation also details the acquisition of Clean Coats and a focus on digital transformation to drive future growth.
முக்கிய அம்சங்கள்
Successfully rebranded from HIL Limited to BirlaNu Limited to align with a modern, global identity.Set an ambitious strategic vision to reach $1 billion in revenue through innovation and expansion.Operates a global manufacturing footprint with 33 units across India, Germany, and Austria.Maintains significant capacities: 1.1 million MT for Roofs and 100k+ MTPA for Pipes and Fittings.Strong market reach with 30,000+ retail points and 21,000+ channel partners worldwide.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the $1 billion vision and the impact of the rebranding on market share. The diversification into construction chemicals and pipes provides a hedge against the cyclical roofing business.
BirlaNu Ltd Recommends ₹15 Dividend and Appoints New CPO Amid FY26 Results
BirlaNu Limited (formerly HIL Limited) has recommended a final dividend of ₹15 per share (150%) for the financial year ended March 31, 2026. The Board also approved the appointment of Mr. Pardha Saradhi Nooney as Chief Procurement Officer to strengthen its senior management. The FY26 financial results reflect the impact of a significant amalgamation involving five companies, which was approved by the NCLT in March 2026. Despite reporting a standalone net loss, the company continues to maintain its audit and governance standards by re-appointing EY as internal auditors.
முக்கிய அம்சங்கள்
Final dividend of ₹15 per share (150% of face value) recommended for FY 2025-26.Appointment of Mr. Pardha Saradhi Nooney as Chief Procurement Officer with 23+ years of experience.Amalgamation of five entities including Crestia Polytech and Topline Industries completed with effective date of April 5, 2024.Re-appointment of Ernst and Young LLP as Internal Auditor for FY 2026-27.Auditor's report indicates a standalone net loss for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should evaluate the consolidated financial health following the merger of five entities to understand the long-term growth trajectory. While the dividend is a positive sign, the standalone loss warrants a cautious review of the full earnings report.
SBI Board Approves Long-Term Fund Raising Up to US$ 2 Billion for FY 2026-27
State Bank of India's Executive Committee has approved a proposal to raise up to US$ 2 billion in long-term funds during the 2026-27 fiscal year. The capital will be raised in single or multiple tranches through public offers or private placements of bonds. These bonds may be fixed or floating rate and denominated in US Dollars or other major foreign currencies. This move is aimed at strengthening the bank's capital base and supporting its international lending operations.
முக்கிய அம்சங்கள்
Approved fund raising of up to US$ 2 billion for the financial year 2026-27Issuance to be conducted under Reg-S/144A via public offer or private placementInstruments include fixed or floating rate bonds in USD or other major foreign currenciesThe decision was finalized during the Executive Committee meeting held on May 12, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a proactive step by SBI to secure foreign currency funding to support its global growth. Monitor the coupon rates of these bonds as they will reflect the bank's credit standing in international markets.
MobiKwik Achieves Full Regulatory Compliance in FY26 Annual Secretarial Audit
One MobiKwik Systems Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The independent audit conducted by Surya Gupta & Associates confirms that the company is in full compliance with all applicable SEBI regulations, including LODR and Insider Trading norms. Importantly, the report indicates zero instances of non-compliance and no regulatory actions or penalties were initiated against the company or its directors during the period. This clean report reinforces the company's commitment to high standards of corporate governance.
முக்கிய அம்சங்கள்
Confirmed 100% compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Zero actions, warnings, or penalties issued by SEBI or Stock Exchanges against the company, promoters, or directors.All mandatory policies were adopted, updated, and reviewed by the Board in accordance with SEBI guidelines.No directors were found disqualified under Section 164 of the Companies Act, 2013.Successful performance evaluation of the Board, Independent Directors, and Committees was conducted for the financial year.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's strong governance framework and clean regulatory record. No immediate action is required as this is a routine but positive confirmation of statutory adherence.
MobiKwik reported a strong performance in its core segments for FY26, with Consumer Payments and Lending achieving all-time high gross margins of 39% and 59% respectively in Q4. While the core business generated ₹50 Cr EBITDA, the company reported a net EBITDA of -₹5 Cr due to a ₹55 Cr strategic reinvestment into its Merchant Payments business. A major milestone was achieved with the acquisition of three key licenses: NBFC, Stock Broking, and Online Payment Aggregator. The company aims for a 10X revenue scale-up in its merchant business by FY28, transitioning from distribution to ownership economics in lending.
முக்கிய அம்சங்கள்
Core business generated ₹50 Cr EBITDA in FY26, representing a ₹74 Cr positive swing in performance.UPI transactions grew 170% YoY to 209.27 Mn, outperforming the industry growth rate of 26%.Secured 3 major regulatory licenses in 12 months: NBFC (RBI), Stock Broking (SEBI), and Payment Aggregator (RBI).Lending risk improved by 35% vs peak stress, with 25% of loans now in Super-Prime and Prime categories.Targeting 10X revenue growth in Offline Merchant business and 10X GMV in Online Merchant business by FY28.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition to an NBFC model, which is expected to unlock better NIMs and product velocity. Monitor the execution of the '4 New Growth Engines' and the progress toward full EBITDA breakeven by FY28.
MobiKwik Reports Q4 FY26 Profit of INR 44 Mn; FY26 EBITDA Nears Breakeven with INR 742 Mn Swing
MobiKwik achieved its second consecutive profitable quarter in Q4 FY26 with a PAT of INR 44 Mn, a significant turnaround from a loss of INR 560 Mn in Q4 FY25. For the full year FY26, the company reported a total income of INR 11,542 Mn and an EBITDA of INR -52 Mn, nearing breakeven with a massive INR 742 Mn improvement YoY. Contribution margins expanded significantly to 38% for the full year, up from 30% in FY25. The company's UPI transaction volume grew 170% YoY, making it the second fastest-growing TPAP in India's UPI ecosystem.
முக்கிய அம்சங்கள்
Q4 FY26 EBITDA stood at INR 174 Mn, marking the second profitable quarter in a row with a INR 632 Mn YoY improvement.Full-year FY26 Contribution Profit grew 21% YoY to INR 4,374 Mn, driven by structural margin expansion.Payments GMV hit an all-time high of INR 1,821 Bn for FY26, representing a 57% growth over the previous year.Financial Services revenue grew 37% YoY in Q4 to INR 771 Mn, supported by a 59% growth in ZIP EMI GMV.H2 FY26 turned PAT positive at INR 84 Mn, effectively absorbing most of the losses incurred in H1 FY26.
👀 கவனிக்க வேண்டியவை
Investors should view the back-to-back profitable quarters and the massive EBITDA swing as a strong signal of a sustainable turnaround. Monitor the scaling of the new Merchant Payments business and the company's ability to maintain baseline profitability in FY27.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
